# Jeffrey A. Sosman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jeffrey-a-sosman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 129,668 |
| Field | Melanoma and MAPK Pathways |
| h-index | 122 |
| i10-index | 355 |
| Last Known Institution | Robert H. Lurie Comprehensive Cancer Center of Northwestern University |
| OpenAlex ID | https://openalex.org/A5075566772 |
| ORCID iD | https://orcid.org/0000-0002-0650-9698 |
| Works | 938 |

## Researcher papers

Showing 12 of 18.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/temsirolimus-interferon-alfa-or-both-for-advanced-renal-cell-carcinoma/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors](https://scholariq.org/papers/i-ras-i-mutations-in-cutaneous-squamous-cell-carcinomas-in-patients-treated-with/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)
- [Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events](https://scholariq.org/papers/society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immune/)
- [Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab](https://scholariq.org/papers/anti-pd-1-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune/)
- [Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/kidney-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy](https://scholariq.org/papers/melanoma-specific-mhc-ii-expression-represents-a-tumour-autonomous-phenotype-and/)
- [Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/management-of-immunotherapy-related-toxicities-version-1-2019-nccn-clinical/)
- [Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade](https://scholariq.org/papers/targeted-next-generation-sequencing-identifies-markers-of-response-to-pd-1/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Robert H. Lurie Comprehensive Cancer Center of Northwestern University](https://scholariq.org/institutions/robert-h-lurie-comprehensive-cancer-center-of-northwestern-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.